Abstract
Objective: To develop and evaluate a deep radiomics model for clinicallysignificant prostate cancer (csPCa, grade group >= 2) detection and compare itsperformance to Prostate Imaging Reporting and Data System (PI-RADS) assessmentin a multicenter cohort. Materials and Methods: This retrospective studyanalyzed biparametric (T2W and DW) prostate MRI sequences of 615 patients (meanage, 63.1 +/- 7 years) from four datasets acquired between 2010 and 2020:PROSTATEx challenge, Prostate158 challenge, PCaMAP trial, and an in-house(NTNU/St. Olavs Hospital) dataset. With expert annotations as ground truth, adeep radiomics model was trained, including nnU-Net segmentation of theprostate gland, voxel-wise radiomic feature extraction, extreme gradient boostclassification, and post-processing of tumor probability maps into csPCadetection maps. Training involved 5-fold cross-validation using the PROSTATEx(n=199), Prostate158 (n=138), and PCaMAP (n=78) datasets, and testing on thein-house (n=200) dataset. Patient- and lesion-level performance were comparedto PI-RADS using area under ROC curve (AUROC [95% CI]), sensitivity, andspecificity analysis. Results: On the test data, the radiologist achieved apatient-level AUROC of 0.94 [0.91-0.98] with 94% (75/80) sensitivity and 77%(92/120) specificity at PI-RADS >= 3. The deep radiomics model at a tumorprobability cut-off >= 0.76 achieved 0.91 [0.86-0.95] AUROC with 90% (72/80)sensitivity and 73% (87/120) specificity, not significantly different (p =0.068) from PI-RADS. On the lesion level, PI-RADS cut-off >= 3 had 84% (91/108)sensitivity at 0.2 (40/200) false positives per patient, while deep radiomicsattained 68% (73/108) sensitivity at the same false positive rate. Conclusion:Deep radiomics machine learning model achieved comparable performance toPI-RADS assessment in csPCa detection at the patient-level but not at thelesion-level.